BioCODE Technologies develops point-of-care rapid testing solutions, including the Biocheck Inflammation™ test, to measure and track inflammation linked to diseases such as cancer and cardiovascular conditions. Their technology provides an affordable screening tool that enables early detection and management of inflammation-related health issues.
Funding
$951K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inflammation is a significant factor in numerous global health challenges, including cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders, which account for over 70% of deaths worldwide. Current methods for screening and tracking inflammation often lack affordability and accessibility, hindering early detection and effective management of these conditions.
Solution
BioCODE Technologies addresses this need with the Biocheck Inflammation™ rapid test, an accessible and affordable point-of-care solution for measuring and tracking inflammation. This technology enables proactive screening and monitoring of inflammation levels, facilitating early intervention and personalized management strategies for individuals at risk or affected by inflammation-related diseases. BioCODE's diagnostic solutions contribute to improved human health and wellbeing through early detection and management of inflammatory conditions. The company also offers microclot detection services through its Biolab facility and sublicenses the methodology to international parties.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and individuals seeking accessible and affordable tools for inflammation screening and monitoring.
Features
- Biocheck Inflammation™ rapid test for point-of-care inflammation measurement
- Affordable screening tool suitable for widespread use
- Enables tracking of inflammation levels over time
- Microclot detection services available at Biolab facility
- Methodology available for sublicense to international parties